Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIANCE: JWCAR029 in R/R Non-Hodgkin's Lymphoma
NCT04089215Phase 2Active, not recruiting
- Sponsor
- Shanghai Ming Ju Biotechnology
- Start
- Jun 2019
- Primary completion
- Sep 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of relmacabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Shanghai Ming Ju Biotechnology. Started Jun 2019; status: active, not recruiting.
02
Drugs
relmacabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04089215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04089215.